Biocon intros tacrolimus capsules

Biocon is offering tacrolimus capsules, following the Food and Drug Administration’s approval in November.

The product is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades, according to the company.

The product is sold under brand names including Protopic and Prograf. 

“The launch of tacrolimus capsules in the United States is another milestone for Biocon that reflects our commitment to continually evaluate and expand our portfolio of complex products to serve patients,” said Siddharth Mittal, Biocon CEO and managing director.